일성아이에스

003120KOSPI의약품 제조업

45.5 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 4.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ilshin IS is a pharmaceutical company specializing in penicillin antibiotics, collaborating with GSK, and producing key products like Augmentin, which generated 15,404 million won in sales. The company develops and sells medications across endocrine, digestive, and circulatory systems, achieving 64,292 million won in domestic sales during the 66th fiscal year.

Number of Employees

194people

Average Salary

51.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

135.00Industry Average 14.800.0Point

9.1x industry avg (risky)

PBR

0.79Industry Average 1.044.0Point

In line with industry avg

ROE

0.30Industry Average 4.421.0Point

Well below industry avg

Debt Ratio

0.31Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.2% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.4% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
삼성물산, 이사회 개편…오세철 사장 "AI·원전 등 신사업 확대"
삼성물산의 이사회 개편 및 신사업 확대, 주주환원 정책 관련 뉴스로 일성아이에스와 직접적인 관련은 없습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (57%)

Current 22,950Won52-week high 28,65052-week low 15,170

1-month return2.0Point

1m -3.97% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업가치제고계획(자율공시)2026-03-27
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18